Vivos extends debt-to-equity conversion deadline with Streeterville to Aug 31, 2026

Vivos Therapeutics, Inc.

Streeterville extends timeframe for converting up to $4.5M debt into perpetual preferred and common stock to August 31, 2026.
Conversion is contingent on Vivos raising at least $2.6M in equity; occurs dollar-for-dollar up to $4.5M.
Extension allows Vivos to conduct planned rights offering and maintain Nasdaq listing compliance.
Original June 5, 2026 agreement had June 15 deadline; Company needed more time to complete equity raise.
CEO Kirk Huntsman expresses gratitude for Streeterville's cooperation and support on new strategic business model.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.